Literature DB >> 16702975

Depressive symptoms and insulin resistance in young adult males: results from the Northern Finland 1966 birth cohort.

M Timonen1, U Rajala, J Jokelainen, S Keinänen-Kiukaanniemi, V B Meyer-Rochow, P Räsänen.   

Abstract

The association between insulin resistance (IR) and depression is a subject of growing research interest, especially as previous population-based studies have presented conflicting findings. The present study extends our understanding about the putative impact of the severity of depressive symptoms on this association and it provides further epidemiological evidence in support of earlier findings, suggesting that the association between IR and depression is present already in young adult males. To determine the impact of the severity of depressive symptoms on the putative association between IR and depression in young adult males, we were given access to the Northern Finland 1966 Birth Cohort database. During the 31-year follow-up survey of this genetically homogeneous birth cohort, IR was assessed by 'Qualitative Insulin Sensitivity Check Index' (QUICKI), and severity of depressive symptoms by 'Hopkins' Symptom Checklist-25' (HSCL-25). This study involved 2,609 male cohort members with complete variable information. In men, the means of the QUICKI-values decreased (i.e., IR increased) in line with the increased severity of depressive symptoms as assessed by HSCL-25 subgroups (analysis of covariance P-value for trend, P=0.003). In multivariate generalized logistic regression analyses, after adjusting for confounders, IR was positively associated with current severe depressive symptoms, the odds ratio (OR) being over threefold (adjusted OR 3.15, 95% confidence interval 1.48-6.68) and the value of OR increased in parallel with a tighter definition of IR (P-value for trend=0.007). The results indicate that in young males, a positive association exists specifically with severe depressive symptoms.

Entities:  

Mesh:

Year:  2006        PMID: 16702975     DOI: 10.1038/sj.mp.4001838

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  22 in total

1.  Association of depression with increased risk of dementia in patients with type 2 diabetes: the Diabetes and Aging Study.

Authors:  Wayne Katon; Courtney R Lyles; Melissa M Parker; Andrew J Karter; Elbert S Huang; Rachel A Whitmer
Journal:  Arch Gen Psychiatry       Date:  2011-12-05

2.  The effect of a 4-week treatment with reboxetine on metabolic parameters of depressed inpatients.

Authors:  Georgios Paslakis; Maria Gilles; Florian Lederbogen; Claudia Schilling; Barbara Scharnholz; Michael Deuschle
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-10-30       Impact factor: 5.270

Review 3.  Functional biomarkers of depression: diagnosis, treatment, and pathophysiology.

Authors:  Heath D Schmidt; Richard C Shelton; Ronald S Duman
Journal:  Neuropsychopharmacology       Date:  2011-08-03       Impact factor: 7.853

4.  Association between Na⁺,K⁺-ATPase activity and the vulnerability/resilience to mood disorders induced by early life experience.

Authors:  Patrícia Pelufo Silveira; André Krumel Portella; Carla da Silva Benetti; Alexandra Ioppi Zugno; Emilene Barros da Silva Scherer; Cristiane Bastos Mattos; Angela T S Wyse; Aldo Bolten Lucion; Carla Dalmaz
Journal:  Neurochem Res       Date:  2011-06-22       Impact factor: 3.996

5.  Curcumin reverses the depressive-like behavior and insulin resistance induced by chronic mild stress.

Authors:  Ji-Duo Shen; Yu Wei; Yu-Jie Li; Jing-Yi Qiao; Yu-Cheng Li
Journal:  Metab Brain Dis       Date:  2017-04-21       Impact factor: 3.584

6.  Bivariate Genome-Wide Association Study of Depressive Symptoms With Type 2 Diabetes and Quantitative Glycemic Traits.

Authors:  Kadri Haljas; Azmeraw T Amare; Behrooz Z Alizadeh; Yi-Hsiang Hsu; Thomas Mosley; Anne Newman; Joanne Murabito; Henning Tiemeier; Toshiko Tanaka; Cornelia van Duijn; Jingzhong Ding; David J Llewellyn; David A Bennett; Antonio Terracciano; Lenore Launer; Karl-Heinz Ladwig; Marylin C Cornelis; Alexander Teumer; Hans Grabe; Sharon L R Kardia; Erin B Ware; Jennifer A Smith; Harold Snieder; Johan G Eriksson; Leif Groop; Katri Räikkönen; Jari Lahti
Journal:  Psychosom Med       Date:  2018-04       Impact factor: 4.312

7.  PPAR-γ agonism as a modulator of mood: proof-of-concept for pioglitazone in bipolar depression.

Authors:  David E Kemp; Martha Schinagle; Keming Gao; Carla Conroy; Stephen J Ganocy; Faramarz Ismail-Beigi; Joseph R Calabrese
Journal:  CNS Drugs       Date:  2014-06       Impact factor: 5.749

8.  Depression and insulin resistance: cross-sectional associations in young adults.

Authors:  Sue Pearson; Mike Schmidt; George Patton; Terry Dwyer; Leigh Blizzard; Petr Otahal; Alison Venn
Journal:  Diabetes Care       Date:  2010-02-25       Impact factor: 19.112

Review 9.  Brain insulin dysregulation: implication for neurological and neuropsychiatric disorders.

Authors:  Rasoul Ghasemi; Leila Dargahi; Ali Haeri; Maryam Moosavi; Zahurin Mohamed; Abolhassan Ahmadiani
Journal:  Mol Neurobiol       Date:  2013-01-20       Impact factor: 5.590

10.  Association of depression with accelerated cognitive decline among patients with type 2 diabetes in the ACCORD-MIND trial.

Authors:  Mark D Sullivan; Wayne J Katon; Laura C Lovato; Michael E Miller; Anne M Murray; Karen R Horowitz; R Nick Bryan; Hertzel C Gerstein; Santica Marcovina; Basil E Akpunonu; Janice Johnson; Jean Francois Yale; Jeff Williamson; Lenore J Launer
Journal:  JAMA Psychiatry       Date:  2013-10       Impact factor: 21.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.